Maria Symiakaki/ LinkedIn
May 29, 2026, 09:50
Maria Symiakaki: Advancing Cardiovascular Prevention at the 2026 Congress of the European Atherosclerosis Society
Maria Symiakaki, Co-Founder and Public Affairs Business Development Director at Solutions for Rare Diseases (SfRD), shared a post on LinkedIn:
“Happy to attend the 2026 Congress of the European Atherosclerosis Society.
It was an excellent opportunity for global leaders in lipidology and preventive cardiology to reconnect, exchange ideas, and explore the future of cardiovascular prevention and lipid management.
Key highlights included the release of the new EAS consensus on pediatric familial hypercholesterolemia (FH), as well as advances in global lipid clinic networks.
Importantly, patient voices continue to play a central role in shaping cardiovascular health policy and care pathways across Europe.”
Stay updated with Hemostasis Today.
-
Jul 13, 2026, 23:39Yaariv Khaykin: Whole-Person Care Can Strengthen Stroke Prevention in Patients With Atrial Fibrillation
-
Jul 13, 2026, 22:33ESOC 2026 recordings are now available on eSTEP – European Stroke Organisation
-
Jul 13, 2026, 20:17Julia R. Coleman: Fantastic First Day at ISTH 2026
-
Jul 13, 2026, 20:11Ruah Alyamany: Combination Therapy Improves Quality of Life in ITP
-
Jul 13, 2026, 19:47Brian O Mahony: Two-Year Results of BBM-H901 Gene Therapy Presented at ISTH 2026
-
Jul 13, 2026, 19:37Sara Zalghout: Connecting With Colleagues From All Over the World at ISTH 2026
-
Jul 13, 2026, 18:54Alfonso J. Tafur: New Evidence on Perioperative Anticoagulation in Cancer at ISTH 2026
-
Jul 13, 2026, 18:42Jessica Garcia: Thrombin Generation in Type 3 VWD With an Inhibitor on Emicizumab
-
Jul 13, 2026, 18:19Fionnuala Ní Áinle: High-Quality Evidence for DVT Diagnosis in Pregnancy at ISTH 2026